[stock_market_widget type=”card” template=”basic2″ assets=”PHG” realtime=”true” api=”yahoo-finance”]
Cardiac arrhythmias, the electrical faults that make a heartbeat too fast, too slow, or out of rhythm, affect millions of people, and one of the most common fixes is a procedure called catheter ablation. A thin wire is threaded into the heart to burn or freeze the tiny patches of tissue causing the problem. For decades this work has been guided by X-ray, which lets doctors see the catheter but not the soft tissue around it, and which bathes both patient and staff in ionizing radiation over long procedures. A small but growing corner of the medical device world is trying to replace that X-ray view with real-time magnetic resonance imaging, the same technology that already produces the detailed heart scans used in diagnosis.
The appeal is straightforward. MRI shows soft tissue in fine detail, so a physician can watch the heart muscle itself rather than guessing from the outline of a wire, check whether a burn actually worked, and spot gaps in the treatment before the patient leaves the room, all without radiation. Building tools that work safely inside a powerful magnetic field is difficult, which is why very few companies operate here. The clearest specialist is Imricor Medical Systems, Inc. (ASX: IMR), a Minnesota-based, Australian-listed maker of MRI-compatible mapping systems and single-use ablation catheters. Its products are already approved in the European Union, Saudi Arabia, and New Zealand, while two of them are cleared in the U.S.
Today that niche got a much larger backer. Royal Philips (NYSE: PHG, AEX: PHIA), the Dutch health-technology group that reported 2025 sales of about $21 billion (EUR 18 billion) and employs roughly 63,700 people, said it was launching a joint interventional MR lab with Imricor. The system pairs Philips’ 1.5T MRI scanner and its AI-assisted cardiac imaging software with Imricor’s NorthStar guidance system, its Advantage-MR recorder, and its Vision-MR family of catheters, creating a single room, which the companies call an iMR lab, where a full ablation can be planned, performed, and checked under live MRI.
What makes this more than a science project is the packaging. Rather than asking a hospital to assemble compatible parts from different vendors, the two firms are offering a complete, ready-to-run setup built on Philips’ helium-free magnet, which is easier to install and can sit closer to a cardiology department. The product is being shown at the ESC Congress 2026 heart conference in Munich, and it is available now in markets that accept the European CE mark, with some configurations available in the U.S. Broader U.S. availability depends on further regulatory clearances.
For a company of Imricor’s size, the arrangement carries real weight. With a market value of roughly $480 million, it is a minnow next to Philips, and selling costly capital equipment to cautious hospital buyers is slow, expensive work for any small firm doing it alone. Having a global imaging leader put its name, sales network, and installed base of scanners behind the technology lowers the risk that buyers feel, and it points Imricor toward the part of the business investors care about most, the steady, repeat revenue from the disposable catheters used in every procedure.
None of this guarantees rapid uptake. MRI-guided ablation is still a new way of working, most of Imricor’s catheters remain outside the U.S. market for now, and hospitals change their habits slowly. What the Philips deal does is move the idea from promising demonstration toward something a hospital can actually buy as one product, backed by a company it already trusts. Whether that translates into meaningful sales will show up over the next few years, but the launch marks the moment the technology stopped being a laboratory curiosity and started looking like a commercial product.
